{"analyses":[{"ciLowerLimit":"0.4105","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.001","groupDescription":"Null Hypothesis: The response rate after two cycles of induction therapy and the presence of a polymorphism are independent in the study population","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7598","paramType":"Odds Ratio (OR)","paramValue":"1.4328","statisticalComment":"Fisher's exact test was used instead of chi-square test due to small expected cell counts.","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96"},{"groupId":"OG001","value":"0.96"},{"groupId":"OG002","value":"0.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"109"}],"units":"Participants"}],"description":"A chi-square test will be used to test whether the response rate after two cycles of induction therapy and the presence of a polymorphism are independent in the study population.","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"},{"description":"Patients that either failed during Induction therapy or refused randomization","id":"OG002","title":"Not Assigned"}],"paramType":"NUMBER","populationDescription":"Eligible patients with available polymorphism data and response data after two cycles of induction therapy. Measure value is the proportion of patients with a polymorphism.","reportingStatus":"POSTED","timeFrame":"Through completion of a participant's first two cycles during induction, including treatment delays, assessed up to 69 days","title":"Proportion of Patients With a Polymorphism","type":"SECONDARY","unitOfMeasure":"Proportion of patients"}